NUVL
Nuvalent, Inc.
NASDAQ · Healthcare · Biotechnology · US
$123.96
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -7.1%
- EBIT
- -36.1%
- EPS
- -38.0%
- Free cash flow
- -53.5%
- Operating cash flow
- -53.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -47.8%
- Net income
- -63.1%
- EPS
- -48.9%
- Free cash flow
- -48.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026